Compare Manhattan Associates Inc (MANH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Zoetis Inc — how do they compare? Manhattan Associates Inc trades at $192.8 (market cap $11.38B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 2.7× Manhattan Associates Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| MANH | ZTS | |
|---|---|---|
Market Cap | $11.38B | $31.14B |
Sector | Technology | Health |
52-Week High | $220.19 | $156.76 |
52-Week Low | $120.88 | $71.91 |
Enterprise Value | $11.25B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH is trading at $192.63, down 1.56% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, valuation ratios remain elevated with a P/E of 55.93 and P/B of 72.26, indicating high investor expectations. Recent news highlights an ongoing legal investigation into fiduciary duties by the Rosen Law Firm, creating a mixed sentiment backdrop.
The outlook for MANH is cautiously optimistic, with a consensus price target of $210.33 offering 9.2% upside potential. Key opportunities include sustained cloud growth and strong profitability metrics like a 96.38% ROE. Risks involve the high valuation, potential legal overhangs from the investigation, and any slowdown in enterprise software demand. Institutional analysts maintain an 80% buy rating, suggesting confidence in execution despite near-term headwinds.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
